Conferences

EASL Congress 2025

Conference Name: EASL Congress 2025

Time: May 7-10, 2025

Location: Amsterdam, the Netherlands

Axcelead will be attending EASL Congress 2025 in Amsterdam, the Netherlands. Visit us at Booth #BS22 to learn how we can empower you at each stage of liver disease drug discovery.

Our scientist, Takumi Sugawara, will also be presenting a poster at the conference. We look forward to meeting you there!

Click here for our liver disease drug discovery services.

Click here for our pharmacology capabiliteis.

Poster Presentation

Title: Identification of differences in therapeutic mechanisms between Resmetirom and Semaglutide on metabolic dysfunction-associated steatohepatitis treatment in western diet-fed melanocortin 4 receptor knockout mice

Presenter: Takumi Sugawara

Date&Time: Friday,May 9th. The presenter will be available during the morning and afternoon coffee breaks throughout the day.

Poster Number: FRI-438

Abstract:
The first MASH therapeutic drug, resmetirom, a THR-β agonist, was approved by the FDA, and semaglutide, a GLP-1 analog, also showed positive effects on MASH patients in a phase III clinical trial. This study simultaneously evaluated these drugs in western diet-fed MC4R-KO mice, which show substantial obesity and insulin resistance similar to that of a patient with MASH. Although both resmetirom and semaglutide improved liver injury and steatosis, there are differences on body composition change and energy expenditure based on their mechanisms. In addition to resmetirom, semaglutide might also be available on the market. As these drugs have different mechanisms of action, combination therapy with them may provide a more effective treatment for MASH.

Axcelead DDP’s Solutions:
Axcelead DDP provides a MASH mouse model by feeding MC4R KO mice a high-fat diet, which closely mimics human MASH pathology, including obesity and insulin resistance. We utilize EchoMRI and the Oxymax system to non-invasively measure body composition, energy expenditure, and respiratory quotient, enabling comprehensive evaluation of drug effects on these parameters.
In addition to pharmacological efficacy studies, we offer a variety of metabolic disease models and a wide range of evaluation services, including pathological assessments and omics analyses. With these capabilities, we provide comprehensive support for metabolic disease research, including studies related to MASH. If you are facing challenges in metabolic disease drug discovery, please feel free to contact us.

Master of Pharmacy. After completing a Master’s program at the Graduate School of Pharmaceutical Sciences, Tohoku University in 2019, joined Taisho Pharmaceutical Co., Ltd., where engaged in drug discovery research focused on fibrotic and renal diseases. In 2023, joined Axcelead Drug Discovery Partners, Inc., and has since been involved in pharmacological efficacy studies in the field of metabolic diseases, including liver and kidney diseases as well as obesity.